Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Legend Biotech (LEGN) Cash & Equivalents: 2018-2024

Historic Cash & Equivalents for Legend Biotech (LEGN) over the last 7 years, with Dec 2024 value amounting to $286.7 million.

  • Legend Biotech's Revenue - Interest and Investment Income rose 3495912.24% to $1.7 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 billion, marking a year-over-year increase of 144628.17%. This contributed to the annual value of -$278,000 for FY2020, which is N/A change from last year.
  • As of FY2020, Legend Biotech's Revenue - Interest and Investment Income stood at -$278,000.
  • In the past 5 years, Legend Biotech's Revenue - Interest and Investment Income registered a high of -$278,000 during FY2020, and its lowest value of -$278,000 during FY2020.
  • Moreover, its 3-year median value for Cash & Equivalents was $786.0 million (2022), whereas its average is $783.5 million.
  • Per our database at Business Quant, Legend Biotech's Cash & Equivalents soared by 446.63% in 2020 and then plummeted by 77.56% in 2024.
  • Legend Biotech's Cash & Equivalents (Yearly) stood at $455.7 million in 2020, then surged by 51.19% to $688.9 million in 2021, then increased by 14.09% to $786.0 million in 2022, then skyrocketed by 62.55% to $1.3 billion in 2023, then tumbled by 77.56% to $286.7 million in 2024.